oa Medical Treatment of Benign Prostatic Hyperplasa Where do we stand in 2004?

References

1. Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockers: a reflection form MTOPS. Curr Opin Urol. 2004; 14::17–20.
   [Google الباحث العلمي]
2. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology. 2001; 58::508–516.
   [Google الباحث العلمي]
3. Akduman B, Crawford ED. Terazosin, doxazosin and prazosin: Current clinical experience. Urology. 2001; 58:Suppl 1:49–54.
   [Google الباحث العلمي]
4. American Urological Association. AUA guidelines on the management of benign prostatic hyperplasia 2003. Available from URL: http://www.auanet.org/timssnet/products/ guidelines/bph_management.cfm.
5. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1 -adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36::1–13.
   [Google الباحث العلمي]
6. Schulowan CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol. 1999; 36::609–620.
   [Google الباحث العلمي]
7. Span PN, Voller MC, Smals AG, Swap EG, Schalken JA, Feneley MR, et al., Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzynamatic activity in the human prostate. J Urol. 1999; 161::332–337.
   [Google الباحث العلمي]
8. Andriole G, Ray P, Humphrey P, Gleave M, Rittmaster R. The impact of dutasteride, a novel dual 5 a-reductase inhibitor on both serum and intraprostatic androgens. Eur Urol suppl. 2003; 2:1:85. (Abstract 332).
   [Google الباحث العلمي]
9. Meconnell JJ, Bruskewitz R, Walsh PC, Andriole G, Lieber MM, Holtgrew e HL, et al., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998; 338::557–563.
   [Google الباحث العلمي]
10. Thompson IM, Goodman PJ, Tangen CM, Lucia ML, Miller GJ, Ford LG, et al., The influence of finasteride in the develop-ment of prostate cancer. N Engl J Med. 2003; 349::211–220.
    [Google الباحث العلمي]
11. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Androile G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase Types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002; 60::434–441.
    [Google الباحث العلمي]
12. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol. 2002; 12::15–18.
    [Google الباحث العلمي]
13. Lowe FC, Fagelman E. Phytotheapy in the treatment of benign prostatic hyperplasia: an update. Urology. 1999; 53::671–678.
    [Google الباحث العلمي]
14. Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004; 14::13–16.
    [Google الباحث العلمي]
15. Abrams P, Kaplans S, Millard R. Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity. Eur Urol. 2002; 1:Suppl:132.
    [Google الباحث العلمي]
16. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003; 326::841–844.
    [Google الباحث العلمي]
17. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al., Combi-nation treatment with an alpha blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomize, controlled study. J Urol. 2002; 169::2253–2256.
    [Google الباحث العلمي]
18. Debryne FM, Jardin A, Colloi D, et al., Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol. 1998; 34::169–175.
    [Google الباحث العلمي]
19. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al., The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Study, Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;:335–539.
    [Google الباحث العلمي]
20. Kirby RS, Roehrborm CG, Boyle P, Bartsch G, Jardin A, Cary MM, et al., Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptoma-tic benign prostatic hyperplasia: The prospective European doxazosin and combination therapy (PREDICT) trial. Urology. 2003; 61::119–126.
    [Google الباحث العلمي]
21. Bautista OM, Kusek JW, Nyberg LM, et al., Study design of the Medical Therapy Of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2001; 24::224–243.
    [Google الباحث العلمي]
22. Mc Connell ID. The impact of medical therapy on the clinical progression of BPH: results of the MTOPS trial [abstract]. J Urol. 2002; 167::1042.
    [Google الباحث العلمي]
23. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170::530–547.
    [Google الباحث العلمي]